Share this article
Share this article
SHANGHAI, Dec. 22, 2020 /PRNewswire/ 111, Inc. ( 111 or the Company ) (NASDAQ: YI), a leading digital healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced the successful completion of new capital injection in its principal PRC subsidiary by a selected group of strategic and mission-driven investors.
On December 22, 2020, 1 Pharmacy Yaofang Technology (Shanghai) Co., Ltd. (previously known as Yao Fang Information Technology (Shanghai) Co., Ltd.) ( Yao Fang Shanghai ), the principal operating subsidiary of 111 in China, completed a new round of capital injection from strategic investors. According to the investment agreements, the investors invested in Yao Fang Shanghai an aggregate of RMB515 million (approximately US$78.75 million